Board of Directors
Mr. Angelo Boujos
Chairman of the Board

As the Chairman, President and CEO of Triton, Angelo Boujos brings more than 20 years of business management, investment and financing experience with a portfolio that includes an international network of specialized funds, investment bankers and broker/dealers. Mr. Boujos is also currently the Managing Director for a group of companies serving the capital markets, specializing in investor relations, management consulting, mergers and acquisitions, and equity financing, which have successfully raised over $80 million in financing since 2004. He developed a strong financial background after spending more than 9 years in a senior management capacity in the financial services industry, 7 years with Toronto Dominion Bank and 2 years with American Express. He became an entrepreneur to pursue an overriding interest in finance and business development and over the next 15 years he owned, operated, and developed numerous successful companies in the service and manufacturing industries.

In 1998, Mr. Boujos entered the fiber optics industry by establishing Canadian Cable Consultants Inc. Building on his expertise of mergers and acquisitions, Mr. Boujos grew this small cable company into a full service corporation winning major contracts with Ontario’s three largest cable TV Operators. Within a few months he acquired F.O.C.C. Fiber Optics Corporation of Canada Inc. and then established Photonics Engineering & Design Inc. In 1999, to better capitalize on the demands of the industry, Mr. Boujos incorporated Universe2U Inc. as the parent company for the corporate structure and to operate as a full service provider. Implementing a solid business plan under his leadership, as Founder and Chairman, the company realized revenues in excess of $12 million in the first full year of operations. Mr. Boujos was also the former President/Owner of Winter Valley Springs Inc. for a period of 5 years in the late eighties and early nineties, and previously worked as senior advisor to the President/CEO of Algonqua Springs Inc. and Culligan Inc., assisting the companies to achieve and exceed their projected forecasts.


Dr. Mark T. Hamann, Ph.D.

Dr. Mark T. Hamann, Ph.D. is a natural products chemist with over 20 years of pharmaceutical industry and research experience in the field of marine natural products chemistry and drug development. He served as lead chemist in pharmaceutical manufacturing before returning to graduate school. Dr. Hamann completed his Ph.D. in Organic Chemistry in 1992 at the University of Hawaii, Honolulu, HI, in the laboratory of the late Professor Paul J. Scheuer. He was postdoctoral fellow in 1993 at McMurdo Sound Antarctica. Dr. Hamann joined the University of Mississippi in 1993 as an Assistant Professor in the Department of Pharmacognosy, where he was promoted to Associate Professor in 1999, and then full Professor in 2005. In addition, Dr. Hamann holds joint faculty positions in the Departments of Pharmacology, Chemistry and Biochemistry, Pharmacy Practice as well as the National Center for Natural Products Research and also serves as an Adjunct Professor at the Center for Marine Biotechnology, University of Mississippi. His research group (15 graduate students and postdoctoral fellows at the University of Mississippi, Department of Pharmacognosy & Pharmacology, is focused on the characterization of prototype drug-leads from chemically defended marine organisms. Dr. Hamann’s main research support is through an NIH R01 which is directed towards the discovery and development of anti-AIDS agents from marine organisms. Dr. Hamann has served as the primary investigator on more than 10 research projects over the past ten years totaling over $6 million in funded research support in addition to directing the chemistry core of the NIH funded ($11 million) Center for Neuropharmacology. Dr. Hamann’s research programs have also been funded by: The World Health Organization, Medicines for Malaria Venture (Gates Foundation), Monsanto Corporate Research, Chiron Pharmaceuticals, Novartis Pharmaceuticals, PharmaMar (Zeltia), Kraft Foods, The Environmental Protection Agency (EPA), NASA, the National SeaGrant Programs (NOAA) and a variety of International Visiting Scholar Programs.

Dr. Hamann’s research has resulted in 107 peer-reviewed journal articles, greater than 58 invited lectures, 120 paper presentations, 7 patents with several pending and 4 book chapters. He is an editor for Biochimica and Biophysica Acta and is on the advisory board for the Journal of Traditional Medicine and regularly serves as a reviewer for internationally recognized peer-reviewed scientific journals as well as federal grant agencies including NIH, NSF and NOAA. Dr. Hamann is a member of the American Chemical Society and has served as the Chair of the Northern Mississippi local ACS section. He is also a member of Sigma Xi, The American Society of Pharmacognosy, The American Association of Colleges of Pharmacy and The American Association for the Advancement of Science.

Publications & Honors